Dihydropyrimidine dehydrogenase (DPD) deficiency screening before fluoropyrimidine therapy — understanding the EU mandate, US guidelines, variant interpretation, and dose modification protocols.
The DPYD gene encodes dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme responsible for metabolizing over 80% of administered 5-fluorouracil. Patients with reduced or absent DPD activity face severe, potentially fatal toxicity from standard fluoropyrimidine doses.
DPD catabolizes approximately 80–85% of 5-FU in the liver. Deficient patients accumulate toxic metabolites (FUTP, FdUMP) at supraphysiologic levels, causing severe myelosuppression, GI toxicity, and neurotoxicity.
DPYD is located on chromosome 1p21.3 and spans 150 kb with 23 exons. Over 160 variants have been identified, but clinical guidelines focus on 4 key variants with strong evidence for toxicity prediction.
All patients being considered for fluoropyrimidine-based chemotherapy — including 5-FU, capecitabine (Xeloda), and tegafur — should undergo DPYD genotyping before treatment initiation. This includes adjuvant, neoadjuvant, and palliative settings across all cancer types.
Three fluoropyrimidine prodrugs and their combinations are directly impacted by DPD metabolizer status.
| Regimen | Fluoropyrimidine | Cancer Types |
|---|---|---|
| FOLFOX | 5-FU + leucovorin | Colorectal, gastric |
| FOLFIRI | 5-FU + leucovorin | Colorectal, pancreatic |
| CAPOX (XELOX) | Capecitabine | Colorectal, gastric |
| FLOT | 5-FU + leucovorin | Gastric, GEJ |
| ECF/ECX | 5-FU or capecitabine | Esophagogastric |
| Cape + RT | Capecitabine | Rectal (neoadjuvant) |
| CMF | 5-FU | Breast |
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend testing for four key DPYD variants with established clinical validity for fluoropyrimidine toxicity prediction.
| Variant | rsID | Activity Score | Frequency (European) | Toxicity Risk |
|---|---|---|---|---|
| DPYD*2A c.1905+1G>A (IVS14+1G>A) | rs3918290 | 0 (no function) | ~1–2% | Very High |
| DPYD*13 c.1679T>G (I560S) | rs55886062 | 0 (no function) | ~0.1% | Very High |
| c.2846A>T (D949V) | rs67376798 | 0.5 (decreased) | ~1–2% | Moderate–High |
| c.1236G>A / HapB3 | rs56038477 | 0.5 (decreased) | ~3–6% | Moderate |
Splice-site variant causing exon 14 skipping and complete loss of DPD function in the affected allele. Heterozygous carriers (activity score 1.0) require 50% dose reduction. Homozygous carriers — contraindicated.
The c.1236G>A variant (proxy for HapB3 haplotype) is the most prevalent clinically actionable variant in European populations. Causes reduced but not absent DPD activity. Dose reduction of 25–50% recommended for heterozygous carriers.
The four CPIC-recommended variants explain only 20–30% of observed DPD deficiency cases. Phenotypic testing (uracil/dihydrouracil plasma ratio) may complement genotyping. Rare or novel variants, epigenetic silencing (DPYD promoter methylation), and non-DPYD pharmacogenes may contribute to unexplained toxicity. Ethnic diversity in variant frequencies means additional population-specific variants may be relevant.
Dose adjustments are based on the DPYD activity score (AS), which correlates with predicted DPD enzyme activity and fluoropyrimidine clearance.
| Activity Score | Phenotype | Dose Recommendation | Follow-up |
|---|---|---|---|
| 2.0 | Normal Metabolizer | Standard dose (100%) | Standard toxicity monitoring |
| 1.5 | Intermediate Metabolizer | Reduce by 25–50% | Titrate up if tolerated after 2 cycles |
| 1.0 | Intermediate Metabolizer | Reduce by 50% | Titrate up with caution; PK monitoring if available |
| 0.5 | Poor Metabolizer | Avoid fluoropyrimidines | Use alternative regimen; if no alternative, reduce by ≥75% with intensive monitoring |
| 0 | Poor Metabolizer | Contraindicated | Use alternative non-fluoropyrimidine regimen |
For patients with activity score 1.0–1.5 who tolerate the initial reduced dose without grade ≥2 toxicity through two complete cycles:
Cycle 1–2: Start at recommended reduced dose (50% for AS 1.0, 75% for AS 1.5)
Cycle 3+: If well tolerated, increase by 10–25% per cycle
Target: Titrate toward standard dose while monitoring for delayed toxicity
Ceiling: Do not exceed standard dose; therapeutic drug monitoring (TDM) of 5-FU plasma levels recommended where available
A streamlined protocol for integrating DPYD testing into oncology clinical workflows.
Flag all patients scheduled for fluoropyrimidine-containing regimens at the point of treatment planning. Include all cancer types — colorectal, gastric, breast, head & neck, pancreatic.
Request testing for the four CPIC-recommended variants (DPYD*2A, *13, c.2846A>T, HapB3). Turnaround time: 5–7 business days for most reference laboratories. Consider adding phenotypic testing (uracil levels) if available.
Calculate the diplotype activity score. Assign metabolizer phenotype. If results are ambiguous or rare variants are detected, consult pharmacogenomics support (MITOTICS® offers clinical variant interpretation).
Apply CPIC-recommended dose modifications based on activity score. For poor metabolizers, select alternative non-fluoropyrimidine regimens. Document pharmacogenomic rationale in the treatment plan.
For intermediate metabolizers on reduced doses, implement structured toxicity assessment after each cycle. Titrate dose upward if tolerated. Consider therapeutic drug monitoring where available.
Record DPYD status in the patient's permanent pharmacogenomic profile. Set EHR alerts for future fluoropyrimidine orders. Inform the patient and provide a pharmacogenomic wallet card.
In April 2020, the European Medicines Agency (EMA) mandated pre-treatment DPYD testing for all fluoropyrimidine-containing therapies across all EU member states — a landmark regulatory decision in pharmacogenomics.
DPYD testing is recommended but not mandated in the US. CPIC guidelines are published, NCCN has added language, and FDA updated 5-FU/capecitabine labeling — but no federal mandate exists. Institutional adoption varies widely. Insurance coverage is improving but inconsistent.
The EU mandate represents the first large-scale, regulator-enforced pharmacogenomic testing requirement in oncology. It has accelerated lab infrastructure, insurance coverage pathways, and clinical education — creating a model for other pharmacogenes (UGT1A1, TPMT, NUDT15).
Use this interactive checklist to prepare for fluoropyrimidine chemotherapy. Click items to mark them complete.
Our pharmacogenomics team can review your genotype report, explain your metabolizer status, and help you discuss dose modifications with your oncologist.
Pharmacogenomics Consultation →